Hasil Pencarian - Brendan Eckelman

  • Menampilkan 1 - 3 hasil dari 3
Perbaiki Hasil
  1. 1
    856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors

    856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors oleh Quinn Deveraux, Heather Kinkead, Kyle Jones, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt, William Crago, Emily Rowell, Elisabeth Torretti

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist

    12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist oleh Quinn Deveraux, Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Garrett Cyprus, Rajay Pandit, James Kalabus, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities

    722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities oleh Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Rajay Pandit, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: